A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.

Estrogen-progestin hormone therapy used to manage menopausal symptoms and other women’s health conditions is associated with a higher risk of developing luminal-like breast cancer subtypes and other ...